Pathogenesis of systemic juvenile idiopathic arthritis: Some answers, more questions

Nature Reviews Rheumatology

Volumn 7, Issue 7, 2011, Pages 416-426

  Mellins, Elizabeth D ^a   MacAubas, Claudia ^a   Grom, Alexei A ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; FERRITIN; GAMMA INTERFERON; GRANZYME B; HAPTOGLOBIN; HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; PERFORIN; PROTEIN S 100; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CELL ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DOWN REGULATION; ERYTHROCYTE LIFESPAN; GENE MUTATION; GENETIC VARIABILITY; GZMB GENE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HLH GENE; HUMAN; IL1A GENE; IL1B GENE; IL1F10 GENE; IL1R1 GENE; IL1R2 GENE; IL1RN GENE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MEFV GENE; MONOCYTE; NLRP3 GENE; NOD2 GENE; NONHUMAN; PHENOTYPE; PRF1 GENE; PRIORITY JOURNAL; PSTPIP1 GENE; RAB27A GENE; REGULATORY T LYMPHOCYTE; REVIEW; SH2D1A GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC26A2 GENE; T LYMPHOCYTE; TH17 CELL; TREATMENT RESPONSE; UNC13D GENE;

ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; RISK FACTORS;

EID: 79959963298     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.68     Document Type: Review

References (116)

1. Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390-392 (2004). (Pubitemid 38160763)
2. Singh-Grewal, D., Schneider, R., Bayer, N. & Feldman, B. M. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 54, 1595-1601 (2006).
3. Sandborg, C. et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J. Rheumatol. 33, 2322-2329 (2006). (Pubitemid 44749796)
4. Spiegel, L. R. et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 43, 2402-2409 (2000).
5. Sawhney, S. & Magalhães, C. Paediatric rheumatology-a global perspective. Best Pract. Res. Clin. Rheumatol. 20, 201-221 (2006).
6. Fujikawa, S. & Okuni, M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan. Acta Paediatr. Jpn 39, 245-249 (1997).
7. Deane, S., Selmi, C., Teuber, S. & Gershwin, M. E. Macrophage activation syndrome in autoimmune disease. Int. Arch. Allergy Immunol. 153, 109-120 (2010).
8. Grom, A. Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum. 50, 689-698 (2004). (Pubitemid 38326166)
9. Sawhney, S., Woo, P. & Murray, K. J. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch. Dis. Child. 85, 421-426 (2001). (Pubitemid 33702300)
10. Behrens, E. M., Beukelman, T., Paessler, M. & Cron, R. Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 34, 1133-1138 (2007). (Pubitemid 46774861)
11. Bleesing, J. et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 56, 965-971 (2007). (Pubitemid 46399444)
12. Lindsley, C. B. Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 30, 838-839 (1987).
13. Oen, K., Fast, M. & Postl, B. Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada, 1975-1992: cycles in incidence. J. Rheumatol. 22, 745-750 (1995).
14. Uziel, Y. et al. Seasonal variation in systemic onset juvenile rheumatoid arthritis in Israel. J. Rheumatol. 26, 1187-1189 (1999). (Pubitemid 29215088)
15. Masters, S., Simon, A., Aksentijevich, I. & Kastner, D. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann. Rev. Immunol. 27, 621-668 (2009).
16. Rigante, D. et al. First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum. 56, 658-661 (2007).
17. Nepom, B. S. & Glass, D. N. Juvenile rheumatoid arthritis and HLA: report of the Park City III workshop. J. Rheumatol. Suppl. 33, 70-74 (1992).
18. Date, Y. et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′-flanking region of the TNFα gene and HLA genes. Arthritis Rheum. 42, 2577-2582 (1999). (Pubitemid 30327174)
19. Fishman, D. et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102, 1369-1376 (1998). (Pubitemid 28467565)
20. Ogilvie, E. M. et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 48, 3202-3206 (2003). (Pubitemid 37409332)
21. Fife, M. S. et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res. Ther. 8, R148 (2006).
22. Moller, J. et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA).Clin. Exp. Rheumatol. 28, 912-918 (2010).
23. Donn, R. P., Shelley, E., Ollier, W. E. & Thomson, W. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 44, 1782-1785 (2001). (Pubitemid 32758224)
24. De Benedetti, F. et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 48, 1398-1407 (2003). (Pubitemid 36554539)
25. Stock, C. J. et al. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun. 9, 349-357 (2008). (Pubitemid 351791491)
26. Lamb, R., Thomson, W., Ogilvie, E. & Donn, R. Positive association of SLC26A2 gene polymorphisms with susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 56, 1286-1291 (2007). (Pubitemid 46608653)
27. Gattorno, M. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505-1515 (2008). (Pubitemid 351705940)
28. Day, T. G. et al. Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. Arthritis Rheum. 58, 2142-2146 (2008). (Pubitemid 351988107)
29. Ayaz, N. A. et al. MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 48, 23-25 (2009).
30. Fall, N. et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 56, 3793-3804 (2007). (Pubitemid 350100712)
31. Macaubas, C. et al. Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin. Immunol. 134, 206-216 (2010).
32. Hinze, C. et al. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res. Ther. 12, R123 (2010).
33. Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479-1486 (2005). (Pubitemid 40664091)
34. Ogilvie, E. M., Khan, A., Hubank, M., Kellam, P. & Woo, P. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 56, 1954-1965 (2007). (Pubitemid 47110394)
35. Barnes, M. et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2102-2112 (2009).
36. Allantaz, F. et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 204, 2131-2144 (2007). (Pubitemid 47360874)
37. Quartier, P. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).Ann. Rheum. Dis. 70, 747-754 (2011).
38. Wilson, D. et al. Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 62, 2510-2516 (2010).
39. Ling, X. et al. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics 10, 4415-4430 (2010).
40. Verbsky, J. & White, A. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31, 2071-2075 (2004). (Pubitemid 39336738)
41. Irigoyen, P. I., Olson, J., Hom, C. & Ilowite, N. T. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum. 50, S437 (2004).
42. Henrickson, M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum. 50, S438 (2004).
43. Muzaffer, M. A. et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J. Rheumatol. 29, 1071-1078 (2002). (Pubitemid 34493516)
44. Nigrovic, P. et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63, 545-555 (2010).
45. Tassi, S. et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1β secretion. Proc. Natl Acad. Sci. USA 107, 9789-9794 (2010).
46. van den Ham, H.-J., de Jager, W., Bijlsma, J. W. J., Prakken, B. J. & de Boer, R. J. Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford) 48, 899-905 (2009).
47. Guma, M. et al. Caspase 1-independent activation of interleukin-1β in neutrophil-predominant inflammation. Arthritis Rheum. 60, 3642-3650 (2009).
48. Joosten, L. A. B. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1 β. Arthritis Rheum. 60, 3651-3662 (2009).
49. Metkar, S. S. et al. Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 29, 720-733 (2008).
50. Frosch, M. et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of Toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 883-891 (2009).
51. Wittkowski, H. et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 58, 3924-3931 (2008).
52. de Benedetti, F. et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34, 1158-1163 (1991).
53. de Benedetti, F. et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142, 4818-4826 (2001). (Pubitemid 33022357)
54. Cazzola, M. et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87, 4824-4830 (1996). (Pubitemid 26162385)
55. Pignatti, P. et al. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J. Rheumatol. 28, 1670-1676 (2001). (Pubitemid 32660643)
56. Muller, K., Herner, E. B., Stagg, A., Bendtzen, K. & Woo, P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Rheumatology (Oxford) 37, 562-569 (1998).
57. Bradshaw, E. M. et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing TH17 cells. J. Immunol. 183, 4432-4439 (2009).
58. Yokota, S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371, 998-1006 (2008). (Pubitemid 351389534)
59. De Benedetti, F. et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial. Arthritis Rheum. 62, S596 (2010).
60. Nakajima, S. et al. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod. Rheumatol. 19, 42-46 (2009).
61. Sarma, P. K., Misra, R. & Aggarwal, A. Elevated serum receptor activator of NF?B ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin. Rheumatol. 27, 289-294 (2008).
62. Silacci, P. et al. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J. Biol. Chem. 273, 13625-13629 (1998). (Pubitemid 28268406)
63. Ling, X. et al. Urine peptidomic and targeted plasma protein analyses in the diagnosis and monitoring of systemic juvenile idiopathic arthritis. Clin. Proteomics 6, 175-193 (2010).
64. Kossakowska, A. E. et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 94, 2080-2089 (1999). (Pubitemid 29430425)
65. de Jager, W. et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 66, 589-598 (2007). (Pubitemid 46707126)
66. Takahashi, A. et al. The role of heme oxygenase-1 in systemic-onset juvenile idiopathic arthritis. Mod. Rheumatol. 19, 302-308 (2009).
67. Martinez, F., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. Front. Biosci. 13, 453-461 (2008). (Pubitemid 351599757)
68. + peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem. 284, 34342-34354 (2009).
69. Srivastava, S. et al. Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis. Clin. Immunol. 136, 257-268 (2010).
70. Porta, C. et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor ?B. Proc. Natl Acad. Sci. USA 106, 14978-14983 (2009).
71. Kristiansen, M. et al. Identification of the haemoglobin scavenger receptor. Nature 409, 198-201 (2001). (Pubitemid 32144285)
72. Avcin, T., Tse, S. M. L., Schneider, R., Ngan, B. & Silverman, E. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J. Pediatrics 148, 683-686 (2006). (Pubitemid 43776910)
73. Schaer, D. et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur. J. Haematol. 74, 6-10 (2005). (Pubitemid 40143680)
74. + immune regulatory network. Blood 107, 1696-1702 (2006). (Pubitemid 43242411)
75. Nistala, K. et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 58, 875-887 (2008). (Pubitemid 351364887)
76. Olivito, B. et al. TH17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis. J. Rheumatol. 36, 2017-2024 (2009).
77. Agarwal, S., Misra, R. & Aggarwal, A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J. Rheumatol. 35, 515-519 (2008). (Pubitemid 351374430)
78. Peck, A. & Mellins, E. Breaking old paradigms: TH17 cells in autoimmune arthritis. Clin. Immunol. 132, 295-304 (2009).
79. Manel, N., Unutmaz, D. & Littman, D. R. The differentiation of human TH17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat. Immunol. 9, 641-649 (2008). (Pubitemid 351714729)
80. Toh, M.-L. et al. Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS ONE 5, e13416 (2010).
81. Koenders, M. et al. Interleukin-1 drives pathogenic TH17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum. 58, 3461-3470 (2008).
82. Donn, R. et al. Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 869-874 (2008). (Pubitemid 351364886)
83. Zhang, K. et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 58, 2892-2896 (2008).
84. Vastert, S. et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 49, 441-449 (2010).
85. Yanagimachi M. et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J. Rheumatol. 38, 769-774 (2011).
86. Shimizu, M. et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 49, 1645-1653 (2010).
87. Imagawa, T. Differences between systemic onset juvenile idiopathic arthritis and macrophage activation syndrome from the standpoint of the proinflammatory cytokine profiles. Arthritis Rheum. 50, S92 (2004).
88. Billiau, A. D., Roskams, T., Van Damme-Lombaerts, R., Matthys, P. & Wouters, C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-γ-producing lymphocytes and IL-6-and TNF-α-producing macrophages. Blood 105, 1648-1651 (2005). (Pubitemid 40223686)
89. Bruck, N. et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J. Clin. Rheum. 17, 23-27 (2011).
90. Filipovich, A. Hemophagocytic lymphohistiocytosis and other hemophagocytic disorders. Immunol. Allergy Clin. North Am. 28, 293-313, viii (2008). (Pubitemid 351522416)
91. Voskoboinik, I., Smyth, M. & Trapani, J. Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol. 6, 940-952 (2006). (Pubitemid 44851736)
92. Wulffraat, N. M., Rijkers, G. T., Elst, E., Brooimans, R. & Kuis, W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 42, 375-379 (2003). (Pubitemid 36312936)
93. Grom, A. A. et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatrics 142, 292-296 (2003). (Pubitemid 36338013)
94. Villanueva, J. et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res. Ther. 7, R30-R37 (2005).
95. de Jager, W. et al. Defective phosphorylation of interleukin-18 receptor β causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2782-2793 (2009).
96. Bufler, P. et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl Acad. Sci. USA 99, 13723-13728 (2002). (Pubitemid 35215448)
97. Mazodier, K. et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106, 3483-3489 (2005). (Pubitemid 41609184)
98. Nold-Petry, C. A. et al. Increased cytokine production in interleukin-18 receptor α-deficient cells is associated with dysregulation of suppressors of cytokine signaling. J. Biol. Chem. 284, 25900-25911 (2009).
99. Sugimoto, T. et al. Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J. Exp. Med. 199, 535-545 (2004). (Pubitemid 38233837)
100. Maeno, N. et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 50, 1935-1938 (2004). (Pubitemid 38725105)
101. Coffey, A. J. et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20, 129-135 (1998). (Pubitemid 28455444)
102. Recalcati, S. et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur. J. Immunol. 40, 824-835 (2010).
103. Lukina, E. A., Levina, A. A., Mokeeva, R. A. & YuN, T. The diagnostic significance of serum ferritin indices in patients with malignant and reactive histiocytosis. Br. J. Haematol. 83, 326-329 (1993). (Pubitemid 23060931)
104. Behrens, E. M. et al. Repeated Toll-like receptor 9 stimulation results in macrophage activation syndrome-like disease in mice. J. Clin. Invest. (in press).
105. Nguyen, K. D. et al. Serum amyloid A overrides TREG anergy via monocyte-dependent and TREG-intrinsic, SOCS3-associated pathways. Blood 117, 3793-3798 (2011).
106. Smith, A. M. et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J. Exp. Med. 206, 1883-1897 (2009).
107. Scott, J. P., Gerber, P., Maryjowski, M. C. & Pachman, L. M. Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis. Arthritis Rheum. 28, 256-261 (1985). (Pubitemid 15133569)
108. Bloom, B., Toyoda, M., Petrosian, A. & Jordan, S. Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis. Rheumatol. Int. 27, 655-660 (2007). (Pubitemid 46625352)
109. Gabay, C., Lamacchia, C. & Palmer, G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6, 232-241 (2010).
110. Church, L., Cook, G. & McDermott, M. Primer: inflammasomes and interleukin 1β in inflammatory disorders. Nat. Clin. Pract. Rheumatol. 4, 34-42 (2008).
111. Gattorno, M. et al. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 56, 3138-3148 (2007). (Pubitemid 47502762)
112. Srikrishna, G. et al. Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells. J. Immunol. 166, 4678-4688 (2001). (Pubitemid 32233755)
113. Newton, R. A. & Hogg, N. The human S100 protein MRP-14 is a novel activator of the β2 integrin Mac-1 on neutrophils. J. Immunol. 160, 1427-1435 (1998). (Pubitemid 28093444)
114. Martinez, F. O., Helming, L. & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Ann. Rev. Immunol. 27, 451-483 (2009).
115. El Chartouni, C., Schwarzfischer, L. & Rehli, M. Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of alternative macrophage priming. Immunobiology 215, 821-825 (2010).
116. Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231-238 (2011).